We love to hear from our listeners. Send us a message. On this week&#x27;s episode of the Business of Biotech, Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing for the late-stage development of neflamapimod in dementia with Lewy bodies (DLB) and commercial planning for an anticipated launch. Winton talks about CMC and manufacturing scale-up, partnership, communicating with regulators and the benefits of global regulatory alignment on protocols for the Phase 3 trial. He also talks about building value through HEOR and payer engagement in parallel with clinical development, and pricing in the context of policy changes and shifting global launch dynamics. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.

Business Of Biotech

[SPEAKER_A] Welcome back to The Business of Biotech. I'm your host, Ben Comer, Chief Editor at Life Science Leader, and today I'm pleased to welcome Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, a clinical-stage company developing Neflamappimod. I'm going to get it right by the end of this.

[SPEAKER_B] Very good. It's very good.

[SPEAKER_A] Neflamappimod for several age-related neurologic disorders. Its lead indication, which entering Phase 3 trials, targets dementia with Lewy bodies. It's received FDA's fast-track designation. Matt joined CervoMed in 2025 after a stint as Chief Operating Officer at Enzyme Pharma, culminating in a $270 million acquisition by BioMarin Pharmaceuticals one year ago last July. Before that, Matt spent 9 years at Biogen, where he was steadily promoted and served as Biogen's Senior Vice President, Head of U.S. Multiple Sclerosis Franchise. Before leaving to join Inazyme. We'll talk with Matt about preparing for late-stage development and scaling up operations at CervoMed, what the commercialization planning looks like, and the nuances of commercializing products for CNS indications. Matt, thank you so much for being here.

[SPEAKER_B] Thanks, Ben. Glad to be here and looking forward to the discussion.

[SPEAKER_A] Yeah, glad to have you. I wanted to start off as we do on The Business of Biotech with your background. You got a PhD from the University of Montreal and then went back to school and got an MBA. Is that right?

[SPEAKER_B] That's right. So too many degrees, but all very important. Sort of the trajectory of my career was always really interested and passionate about science growing up. And so all through university and through grad school, I was really focused on science. Following PhD in Montreal, moved down to Philadelphia here in the US and did a postdoctoral fellowship.

Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.